Ruiz-Delgado GJ, Hernández-Reyes J, González-Ramírez MP, Martagón-Herrera NÁ, Garcés-Eisele J, Ruiz-Argüelles A, González-Cortés A, Ruiz-Argüelles GJ

Language: Spanish
References: 10
Page: 582-587
PDF size: 71.50 Kb.

ABSTRACT

Donor-derived malignancies after allogeneic hematopoietic stem cell transplantation and after solid organ transplantation are considered as rare diseases. We have prospectively searched for donor cell leukemia in a 12-year period, in a single institution, in a group of 106 consecutive patients allografted because of leukemia. We have identified seven cases of donor cell leukemia; six were allografted because of relapsed acute lymphoblastic leukemia and one because of paroxysmal nocturnal hemoglobinuria/ aplastic anemia. These figures suggest that the real incidence of donor cell leukemia has been underestimated. The six patients with lymphoblastic donor cell leukemia were treated prospectively with a pediatric-inspired combined chemotherapy schedule designed for de novo acute leukemia. A complete response was obtained in three out of six patients with lymphoblastic donor cell leukemia. It is possible to obtain favorable responses in donor cell leukemia patients employing combined chemotherapy. The longterm donor cell leukemia survivors remain as full chimeras and have not needed a second transplant..

REFERENCES

1. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Garcés-Eisele J. Donor cell leukemia: A critical review. Leuk Lymphoma. 2007;48:25-38.

2. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Garcés-Eisele J, et al. Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: A single institution experience. Leuk Lymphoma. 2006;47:1952-5.

3. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Calderón-Meza E, et al. Donor-derived hairy cell leukemia. Leuk Lymphoma. 2009,50:1712-4.

4. Kanamori Y, Kayukawa S, Kikuchi T, et al. Case report: A case of donor- derived diffuse large B-cell lymphoma after 24-year remission of acute myeloid leukemia followed by successful allogeneic bone marrow transplantation. Nihom Naika Gakkai Zasshi. 2013;102:721-3.

5. Weigert O, Kapp N, Lane AA, et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discover. 2012;2:47-55.

6. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl. 2000;25:131-3.

7. Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno J, et al. Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: A single institution experience. Leuk Lymphoma. 2011;52:314-6.

8. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-63.

9. Wang E, Hutchinson CB, Huang Q, et al. Donor cell-derived leukemias / myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients. Am J Clin Pathol. 2011;135:525-40.

10. Hertenstein B, Hambach L, Bacigalupo A, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation – a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005;90:969-75.